This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0349-19
**Market Applicability**

| Market | DC | FL & FLH | FL MMA | FL LTC | GA | KS | KY | MD | NJ | NV | NY | TN | TX | WA |
|--------|----|----------|--------|--------|----|----|----|----|----|----|----|----|----|----|----|
| Applicable | X | X | NA | NA | X | X | X | X | X | X | NA | NA | X |

*FHK - Florida Healthy Kids

---

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0349-19
This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0349-19

---

**Market Applicability**

<table>
<thead>
<tr>
<th>Market</th>
<th>DC</th>
<th>FL &amp; FHK</th>
<th>FL MMA</th>
<th>FL LTC</th>
<th>GA</th>
<th>KS</th>
<th>KY</th>
<th>MD</th>
<th>NJ</th>
<th>NV</th>
<th>NY</th>
<th>TN</th>
<th>TX</th>
<th>WA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicable</td>
<td>X</td>
<td>X</td>
<td>NA</td>
<td>NA</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>NA</td>
<td>NA</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

*FHK- Florida Healthy Kids

A. In the treatment of individuals with metastatic colon, rectal, colorectal, or small bowel adenocarcinoma when the following criteria are met:
   1. Bevacizumab is being used in combination with 5FU-based chemotherapy, irinotecan or oxaliplatin; **AND**
   2. Individual has not progressed on more than two lines of a bevacizumab-containing chemotherapy agent;

**OR**

**VI. Endometrial Carcinoma:**
A. In the treatment of individuals with advanced or recurrent endometrial carcinoma when the following are met:
   1. Bevacizumab is being used in combination with carboplatin and paclitaxel; **OR**
   2. Following combination therapy with carboplatin and paclitaxel, bevacizumab is being used as single-agent maintenance therapy until disease progression or prohibitive toxicity;

**OR**

**VII. Malignant Mesothelioma:**
A. In the treatment of individuals with unresectable malignant mesothelioma when the following criteria are met:
   1. Bevacizumab is being used in a first-line combination chemotherapy with cisplatin or carboplatin and pemetrexed; **AND**
   2. Individual has an Eastern Cooperative Oncology Group performance status of 0-2 and no history of bleeding or thrombosis;

**OR**

B. As maintenance therapy in the treatment of individuals with unresectable malignant mesothelioma when all of the following criteria are met:
   1. Bevacizumab was previously administered as an agent in a first-line combination chemotherapy regimen; **AND**
   2. Bevacizumab is being used as a single agent; **AND**
   3. Bevacizumab is being used until disease progression*;

*Note: Once disease progression has occurred, bevacizumab is not to be re-instituted.

**OR**

---
VIII. Non-Small Cell Lung Cancer:
   A. As a first-line treatment of non-squamous, non-small cell lung cancer (NSCLC) when an individual has a current Eastern Cooperative Oncology Group performance status of 0-1, no history of hemoptysis, and the following criteria are met:
      1. Bevacizumab is being used for unresectable, locally advanced, recurrent or metastatic disease in combination chemotherapy with platinum-based therapy and a taxane or pemetrexed; OR
      2. Bevacizumab is being used for recurrent or metastatic disease in combination chemotherapy with platinum-based therapy, a taxane, and atezolizumab;

   OR

   B. As maintenance therapy in the treatment of an individual with non-squamous NSCLC when bevacizumab was previously administered as an agent in first-line combination chemotherapy regimen, is used until disease progression, and the following criteria are met:
      1. Bevacizumab is being used for unresectable, locally advanced, recurrent or metastatic disease as a single agent; OR
      2. Bevacizumab is being used for recurrent or metastatic disease as a single agent or in combination with atezolizumab;

IX. Ovarian Cancer:
   A. In the treatment of individuals with recurrent, metastatic epithelial ovarian cancer, fallopian tube cancer or recurrent primary peritoneal cancer when all of the following criteria are met:
      1. Bevacizumab is being used as a single agent or in combination with other chemotherapy; AND
      2. Bevacizumab is being used in a single line of therapy; AND
      3. Bevacizumab is being used for relapsed or refractory disease;

   OR

   B. In the treatment of individuals with advanced or metastatic epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection when the following criteria are met:
      1. Bevacizumab is being used in combination with other chemotherapy; AND

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0349-19
2. Bevacizumab is being used in a single line of therapy;

**OR**

C. As maintenance therapy in individuals with recurrent, metastatic epithelial ovarian cancer, fallopian tube cancer or recurrent primary peritoneal cancer when all of the following criteria are met:
   1. Bevacizumab was previously administered as an agent in a first-line combination chemotherapy regimen; **AND**
   2. Bevacizumab is being used as a single agent; **AND**
   3. Bevacizumab may be used until disease progression;

**OR**

D. In the treatment of individuals with advanced or metastatic epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection when the following criteria are met:
   1. Bevacizumab was previously administered as an agent in a combination chemotherapy regimen following surgical resection; **AND**
   2. Bevacizumab is being used as a single agent; **AND**
   3. Bevacizumab may be used until disease progression;

**OR**

X. Post-Radiation Necrosis:
   A. In the treatment of individuals with symptomatic post-radiation necrosis of the central nervous system;

**OR**

XI. Renal Cell Carcinoma:
   A. In the treatment of individuals with renal carcinoma (RCC) when the following criteria are met:
      1. Bevacizumab is being used in first-line treatment of metastatic clear cell RCC in combination with interferon; **OR**
      2. Bevacizumab is being used as a single agent for relapsed or medically unresectable stage IV disease with predominant clear cell histology in individuals who have progressed on prior cytokine therapy; **OR**
      3. Bevacizumab is being used as a single agent for relapsed or medically unresectable stage IV disease with non-clear-cell histology; **OR**
      4. Bevacizumab is being used for relapsed or medically unresectable stage IV non-clear cell RCC (including papillary RCC and hereditary leiomyomatosis and RCC [HLRCC]), in combination with erlotinib or everolimus;

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
CRX-ALL-0349-19
OR

XII. Soft Tissue Sarcoma:
   A. In the treatment of individuals with angiosarcoma AND is bevacizumab is being used as a single agent; OR
   B. In the treatment of individuals with solitary fibrous tumor and hemangiopericytoma and individual is using bevacizumab in combination with temozolomide.

Avastin (bevacizumab), Mvasi (bevacizumab-awwb) may not be approved in the treatment of all other conditions when the criteria above are not met, including but not limited to any of the following:

I. Adjuvant therapy following surgery for stage II or III adenocarcinoma of the colon; OR
II. Prostate cancer; OR
III. Carcinoid tumors; OR
IV. Metastatic melanoma; OR
V. Metastatic adenocarcinoma of the pancreas; OR
VI. Metastatic breast cancer, second line therapy or greater, for example when progression noted following anthracycline and taxane chemotherapy; OR
VII. Neurofibromatosis type 2; OR
VIII. Treatment of a single condition with concomitant bevacizumab use with other targeted biologic agents (including but not limited to erlotinib, cetuximab, panitumumab, trastuzumab, lapatinib and ziv-aflibercept); OR
IX. When used in combination with the same irinotecan based regimen that was previously used in combination with ziv-aflibercept.

Note: Avastin (bevacizumab), Mvasi (bevacizumab-awwb) have black box warnings for gastrointestinal perforations, surgery and wound healing complications, and hemorrhage. Gastrointestinal Perforations: The incidence of gastrointestinal perforation, some fatal, in patients receiving bevacizumab ranges from 0.3 to 3.2%. Discontinue bevacizumab in patients who develop gastrointestinal perforation.
Surgery and Wound Healing Complications: The incidence of wound healing and surgical complications, including serious and fatal complications, is increased in patients receiving bevacizumab. Discontinue bevacizumab in patients with wound dehiscence. The appropriate interval between termination of bevacizumab and subsequent elective surgery required to reduce the risks of impaired healing/wound dehiscence has not been determined. Discontinue

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
Market Applicability

| Market         | DC | FL & FHK | FL MMA | FL LTC | GA | KS | KY | MD | NJ | NV | NY | TN | TX | WA |
|----------------|----|---------|--------|--------|----|----|----|----|----|----|----|----|----|----|----|
| Applicable     | X  | X       | NA     | NA     | X  | NA | X  | X  | X  | X  | X  | NA | NA | X  |

*FHK- Florida Healthy Kids

at least 28 days prior to elective surgery. Do not initiate bevacizumab for at least 28 days after surgery and until the surgical wound is fully healed.

Hemorrhage: Severe or fatal hemorrhage, including hemoptysis, gastrointestinal bleeding, hematemesis, central nervous system (CNS) hemorrhage, epistaxis, and vaginal bleeding occurred up to 5-fold more frequently in patients receiving bevacizumab. Do not administer bevacizumab to patients with a recent history of hemoptysis. Discontinue in patients who develop Grade 3-4 hemorrhage.

State Specific Mandates

<table>
<thead>
<tr>
<th>State name</th>
<th>Date effective</th>
<th>Mandate details (including specific bill if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Key References:

8. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0349-19
Market Applicability

| Market | DC | FL & FHK | FL MMA | FL LTC | GA | KS | KY | MD | NJ | NV | NY | TN | TX | WA |
|--------|----|----------|--------|--------|----|----|----|----|----|----|----|----|----|----|----|
| Applicable | X | X | NA | NA | X | NA | X | X | X | X | NA | NA | X |

*FHK- Florida Healthy Kids


